Archive
Late Movers: Apple gains after report of iPhone production cuts
Sears edged up after a judge gave Chairman Eddie Lampert another chance to buy the retailer out of bankruptcy and save 50,000 jobs
Company
NYSE:STZ
Constellation Brands Inc is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand and Italy.
92 stories · page 3 of 5
Archive
Sears edged up after a judge gave Chairman Eddie Lampert another chance to buy the retailer out of bankruptcy and save 50,000 jobs
Investments and investor services
The New York-headquartered group said it expects to earn between $9.20 and $9.30 per share for its 2019 fiscal year
Cannabis stocks dropped Tuesday, despite news that Congress was close to finishing a farm bill, which includes provisions to legalize hemp
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals in Tuesday’s election
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals Tuesday
Voters in Michigan, North Dakota, Missouri and Utah will vote on marijuana proposals Tuesday
Auxly Cannabis recently closed its acquisition of Uruguay-based cannabis company Inverell S.A.
Big names in cannabis, including Aurora Cannabis and Cronos, fared well Friday afternoon
The transaction, which was unveiled last August, has been approved by a majority of Canopy Growth shareholders
The patent details how the system would share information using smart contracts added to the blockchain
Company wants to take advantage of the move by major beverage players into the cannabis sector
At the same time, the Canadian cannabis grower doesn't deny that talks are happening
Co-CEO Mark Zekulin says that through federally legal means and with the right partners, Canopy can create a US-based center of expertise for cannabis and cannabinoids research
Constellation Brands CEO Rob Sands said the Corona beer maker is “extremely bullish” on its investment in Canadian cannabis company Canopy Growth
The maker of Corona beer increased its fiscal 2019 guidance to a range of $9.60 a share to $9.75 a share, from its previous estimate of $9.40 a share to $9.70 a share
Roth Capital analyst Scott Fortune reiterated a Neutral rating, but removed Tilray’s price target
The study is being led by one of Australia’s leading sleep research centres.
Investments and investor services
Bob Byrne explains why the recent hype-filled price action that surrounded Tilray shares does not appear to have dampened the prospects of this still immature and momentum-driven industry
Stifel analyst Christopher Growe credits Canopy Growth’s deal with Constellation Brands with starting the surge
Tilray stock prices doubled and the stock was halted -- twice -- Wednesday after it received approval to export a medical cannabis product to the US the day before